<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the results of 65 patients with treatment-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) who were transplanted from an autograft and reported to the EBMT </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n = 31), or peripheral blood progenitor cells (n = 30), or the combination of both (n = 4) </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> was <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (n = 37), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (n = 13), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 10), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 2) or myeloproliferative syndromes (n = 3) </plain></SENT>
<SENT sid="3" pm="."><plain>The types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were as follows: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (n = 1; 2%), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (n = 3; 5%), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 56; 87%) </plain></SENT>
<SENT sid="4" pm="."><plain>The median time between diagnosis and transplantation was 5 months (range, 3-86) </plain></SENT>
<SENT sid="5" pm="."><plain>The Kaplan-Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%) </plain></SENT>
<SENT sid="8" pm="."><plain>Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs non-CR1: 3 years: 48 vs 89%; P = 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; P = 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>In a multivariate analysis, transplantation in CR1 age as well as their interaction influenced overall survival significantly </plain></SENT>
<SENT sid="11" pm="."><plain>Autologous transplantation may cure a substantial number of patients with treatment-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, especially if they are in CR1 and of younger age </plain></SENT>
</text></document>